NASDAQ:STDY - Steadymed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.60 +0.10 (+2.22 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$4.60
Today's Range$4.55 - $4.65
52-Week Range$2.60 - $6.80
Volume682,899 shs
Average Volume175,821 shs
Market Capitalization$119.81 million
P/E Ratio-10.70
Dividend YieldN/A
SteadyMed Ltd., together with its subsidiaries, operates as a specialty pharmaceutical company that focuses on the development and commercialization of drug product candidates for the treatment of orphan and high-value diseases with unmet parenteral delivery needs. The company's product candidates are enabled by its proprietary PatchPump, a discreet, water-resistant, and disposable drug administration technology. Its lead drug product candidate is Trevyent that is used for treating pulmonary arterial hypertension. The company also develops two drug product candidates for the treatment of post-surgical and acute pain in the home setting. It has operations in Israel, the United States, and Europe. SteadyMed Ltd. was founded in 2005 and is headquartered in San Ramon, California.

Receive STDY News and Ratings via Email

Sign-up to receive the latest news and ratings for STDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio8.51
Quick Ratio8.51


Trailing P/E Ratio-10.70
Forward P/E Ratio-6.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million
Price / Sales114.48
Cash FlowN/A
Price / CashN/A
Book Value$0.90 per share
Price / Book5.11


EPS (Most Recent Fiscal Year)($0.43)
Net Income$-23,200,000.00
Net Margins-2,177.00%
Return on Equity-68.96%
Return on Assets-36.42%


Outstanding Shares26,630,000
Market Cap$119.81

Steadymed (NASDAQ:STDY) Frequently Asked Questions

What is Steadymed's stock symbol?

Steadymed trades on the NASDAQ under the ticker symbol "STDY."

How were Steadymed's earnings last quarter?

Steadymed Ltd (NASDAQ:STDY) released its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.18. Steadymed had a negative return on equity of 68.96% and a negative net margin of 2,177.00%. View Steadymed's Earnings History.

When is Steadymed's next earnings date?

Steadymed is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Steadymed.

What is the consensus analysts' recommendation for Steadymed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steadymed in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Steadymed's key competitors?

Who are Steadymed's key executives?

Steadymed's management team includes the folowing people:
  • Mr. Jonathan M. N. Rigby, Pres, CEO & Director (Age 50)
  • Mr. David W. Nassif, Exec. VP & CFO (Age 64)
  • Mr. Robert Zwolinski, Sr. VP of Operations
  • Ms. Marylyn Rigby, Sr. Director of Investor Relations and Marketing
  • Mr. Carl Hicks Jr., Editor & Chief of

When did Steadymed IPO?

(STDY) raised $56 million in an initial public offering on Friday, March 20th 2015. The company issued 4,300,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

Has Steadymed been receiving favorable news coverage?

Media coverage about STDY stock has been trending positive this week, Accern Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Steadymed earned a coverage optimism score of 0.26 on Accern's scale. They also gave headlines about the company an impact score of 44.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Steadymed's major shareholders?

Steadymed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include UNITED THERAPEUTICS CORP (43.30%) and ORBIMED ADVISORS LLC (13.90%). Company insiders that own Steadymed stock include David W Nassif, Jonathan Rigby, Keith Bank and Orbimed Advisors Llc. View Institutional Ownership Trends for Steadymed.

How do I buy shares of Steadymed?

Shares of STDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Steadymed's stock price today?

One share of STDY stock can currently be purchased for approximately $4.60.

How big of a company is Steadymed?

Steadymed has a market capitalization of $119.81 million and generates $1.07 million in revenue each year. The company earns $-23,200,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. Steadymed employs 26 workers across the globe.

How can I contact Steadymed?

Steadymed's mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company can be reached via phone at 925-272-4999 or via email at [email protected]

MarketBeat Community Rating for Steadymed (NASDAQ STDY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Steadymed and other stocks. Vote "Outperform" if you believe STDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.